



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

ESPS manuscript NO: 20152

Title: State of the art biological therapies in pancreatic cancer

Reviewer's code: 00502831

Reviewer's country: Japan

Science editor: Xue-Mei Gong

Date sent for review: 2015-05-30 09:06

Date reviewed: 2015-06-03 20:17

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The prognosis of pancreatic ductal adenocarcinoma (PDAC) is very poor. Effective targeting therapy for PDAC was thought to be needed. The author reported a summary of the main clinical trials referring to biological therapies evaluation in pancreatic cancer treatment. I think this review article is useful and significant for understanding of actual clinical trials of molecular targeting therapy for PDAC.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

ESPS manuscript NO: 20152

Title: State of the art biological therapies in pancreatic cancer

Reviewer's code: 03104216

Reviewer's country: India

Science editor: Xue-Mei Gong

Date sent for review: 2015-05-30 09:06

Date reviewed: 2015-06-22 03:33

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The review article "State of the art of biological therapies in pancreatic cancer: has a better understanding of the tumor molecular biology really improved targeted therapies applications?" by Di MracoM et. al. is a nice attempt to bring together existing trials in drugs for pancreatic cancer. They have precisely described how understanding of mol bio of tumors is playing an important role in identifying new targets for drug development. In my opinion the manuscript is acceptable with few mionr changes. Comments: 1. The title is very long and it will be better to provide a brief title for review. 2. Conclusion and future challenges can be described in two separate sub headings to give more insight regarding trial failures reasons and complications. 3. The authors only focused on general trials and reviews are already there on that. It could have been better if they also include antibody drug conjugates or nanotechnology based targeted therapies for pancreatic cancer to give a complete over-view of recent progress for pancreatic cancer therapies.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

ESPS manuscript NO: 20152

Title: State of the art biological therapies in pancreatic cancer

Reviewer's code: 02823000

Reviewer's country: South Korea

Science editor: Xue-Mei Gong

Date sent for review: 2015-05-30 09:06

Date reviewed: 2015-06-09 05:53

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Pancreatic cancer is hard to treat, and more studies on targeted therapy are published than ever. It is nice to have a review article that summarizes the progress. Major points 1. I have to ask what is the purpose of mentioning molecular characteristics of pancreatic ductal adenocarcinoma in the beginning. It seems that the authors mentioned them again in beginning of each targeted therapy. Also, some contents had nothing to do with following targeted therapy. 2. Overall structure of the manuscript is fragmented by small pieces. The authors are eager to show a lot of information of failed clinical trials. More condensed and organized writing is recommended. 3. Since almost every year new targeted therapies are tried, and papers about them are published, it is very important to gather the most recent information. However, this paper seemed missed some new, but important information. For example, it failed to mention that direct inhibitor of Kras was developed. The results from several new targeted therapy reported at AACR and ASCO such as Phase 1 Trial of MM-141 and Demcizumab are missing. 4. Are those reasons for unsatisfying results listed in the conclusion the authors' thought or from other sources?



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

ESPS manuscript NO: 20152

Title: State of the art biological therapies in pancreatic cancer

Reviewer's code: 00043819

Reviewer's country: Italy

Science editor: Xue-Mei Gong

Date sent for review: 2015-05-30 09:06

Date reviewed: 2015-06-06 16:44

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This is a review of molecular targeted therapies in pancreatic ductal adenocarcinoma. Although clinical application of these drugs have a little impact on patients' survival until now, many efforts are required for the search of better agents. The manuscript is well-written, and I think it is useful as the state of art of biological therapy of pancreatic cancer.